Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3039% above fair value
$0.54+0.01 (+2.66%)
Close on Nov 16, 2026Market cap $75.32MP/E –Yield –
Rani Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Rani Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.31M, down 26.9% year over year. For fiscal 2025 it was $20.21M, down 24.3% from the year before. The highest annual figure on record is $39.62M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.21M | -24.3% |
| FY2024 | Dec 31, 2024 | $26.68M | -32.7% |
| FY2023 | Dec 31, 2023 | $39.62M | +8.2% |
| FY2022 | Dec 31, 2022 | $36.61M | +38.2% |
| FY2021 | Dec 31, 2021 | $26.48M | +119.9% |
| FY2020 | Dec 31, 2020 | $12.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.02M | -8.9% |
| Q1 FY2026 | Mar 31, 2026 | $5.16M | -21.4% |
| Q4 FY2025 | Dec 31, 2025 | $4.91M | -27.9% |
| Q3 FY2025 | Sep 30, 2025 | $3.22M | -47.8% |
| Q2 FY2025 | Jun 30, 2025 | $5.51M | -10.0% |
| Q1 FY2025 | Mar 31, 2025 | $6.57M | -13.4% |
| Q4 FY2024 | Dec 31, 2024 | $6.81M | -10.5% |
| Q3 FY2024 | Sep 30, 2024 | $6.17M | -45.0% |
| Q2 FY2024 | Jun 30, 2024 | $6.12M | -44.8% |
| Q1 FY2024 | Mar 31, 2024 | $7.59M | -21.9% |
| Q4 FY2023 | Dec 31, 2023 | $7.61M | -26.8% |
| Q3 FY2023 | Sep 30, 2023 | $11.22M | +23.3% |
| Q2 FY2023 | Jun 30, 2023 | $11.09M | +16.4% |
| Q1 FY2023 | Mar 31, 2023 | $9.71M | +27.9% |
| Q4 FY2022 | Dec 31, 2022 | $10.39M | +40.0% |
| Q3 FY2022 | Sep 30, 2022 | $9.10M | -23.9% |
| Q2 FY2022 | Jun 30, 2022 | $9.53M | +153.5% |
| Q1 FY2022 | Mar 31, 2022 | $7.59M | +126.8% |
| Q4 FY2021 | Dec 31, 2021 | $7.42M | +122.3% |
| Q3 FY2021 | Sep 30, 2021 | $11.96M | +472.2% |
| Q2 FY2021 | Jun 30, 2021 | $3.76M | +47.0% |
| Q1 FY2021 | Mar 31, 2021 | $3.35M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.34M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.09M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.56M | – |
See a number that looks wrong?